However, with the advent of the CRISPR base-editing technology, it is now possible to introduce point mutations and other sequence variations, as demonstrated in case of the residue R882, the mutational hotspot of DNMT3A linked to hematologic malignancies. This evidence concerns the gene DNMT3A and hematologic disorder.